Yang‐Gun Suh, Ja Kyung Kim, Jin‐Seok Byun, Hyon‐Seung Yi, Young‐Sun Lee, Hyuk Soo Eun, So Yeon Kim, Kwang‐Hyub Han, Kwan Sik Lee, Gregg Duester, Scott L. Friedman, Won‐Il Jeong – 27 April 2012 – Clinical trials and animal models suggest that infusion of bone marrow cells (BMCs) is effective therapy for liver fibrosis, but the underlying mechanisms are obscure, especially those associated with early effects of BMCs. Here, we analyzed the early impact of BMC infusion and identified the subsets of BMCs showing antifibrotic effects in mice with carbon tetrachloride–induced liver fibrosis.

Erica L. Clinkenbeard, James E. Butler, Brett T. Spear – 27 April 2012 – We previously showed that mouse alpha‐fetoprotein (AFP) enhancer 3 activity is highly restricted to pericentral hepatocytes in the adult liver. Here, using transgenic mice, we show that the upstream enhancer of the rat glutamine synthetase gene is also active, specifically in pericentral regions. Activity of both enhancers is lost in the absence of β‐catenin, a key regulator of zonal gene expression in the adult liver.

Karen F. Murray, Leszek Szenborn, Jacek Wysocki, Stephen Rossi, Amoreena C. Corsa, Phillip Dinh, John McHutchison, Phillip S. Pang, Luminita M. Luminos, Malgorzata Pawlowska, Jacek Mizerski – 27 April 2012 – Tenofovir disoproxil fumarate (DF) is highly effective for the suppression of hepatitis B virus (HBV) in chronically infected adults. This study evaluated the safety and efficacy of tenofovir DF in adolescents with chronic hepatitis B (CHB).

Peter Ferenci – 26 April 2012 – Watch the interview with the authors

Corinne Wentworth‐Kotara, P.A‐C. – 26 April 2012 – Watch the interview with the authors

Anna S. Lok – 26 April 2012 – Watch the interview with the authors

Chiara Gabbi, Jan‐Åke Gustafsson – 26 April 2012

Edoardo G. Giannini, Simona Marenco, Giacomo Borgonovo, Vincenzo Savarino, Fabio Farinati, Paolo Del Poggio, Gian Ludovico Rapaccini, Maria Anna Di Nolfo, Luisa Benvegnù, Marco Zoli, Franco Borzio, Eugenio Caturelli, Maria Chiaramonte, Franco Trevisani, for the Italian Liver Cancer (ITA.LI.CA) group – 26 April 2012 – Alpha‐fetoprotein is a tumor marker that has been used for surveillance and diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis. The prognostic capability of this marker in patients with HCC has not been clearly defined.

Amol S. Rangnekar, Robert J. Fontana – 26 April 2012 – Watch the interview with the authors

Syed‐Mohammed R. Jafri, Stuart C. Gordon – 26 April 2012 – Watch the interview with the authors